

Pablo Chicharro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/73480/publications.pdf>

Version: 2024-02-01

33
papers

306
citations

1162889

8
h-index

887953

17
g-index

34
all docs

34
docs citations

34
times ranked

486
citing authors

#	ARTICLE	IF	CITATIONS
1	Geometric border as a marker for melanoma diagnosis: Study of 200 consecutive melanocytic lesions. <i>Dermatologic Therapy</i> , 2021, 34, e14617.	0.8	1
2	SDRIFE-like rash associated with COVID-19, clinicopathological correlation. <i>Australasian Journal of Dermatology</i> , 2021, 62, 88-89.	0.4	18
3	Multiple adult xanthogranuloma with upper airway involvement. <i>International Journal of Dermatology</i> , 2021, 60, e317-e319.	0.5	1
4	Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases. <i>JAAD Case Reports</i> , 2021, 12, 58-59.	0.4	87
5	Growth arrest and DNA damage-inducible proteins (GADD45) in psoriasis. <i>Scientific Reports</i> , 2021, 11, 14579.	1.6	11
6	Heterotopic Salivary Gland Tissue. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 949-949.	0.2	1
7	Encefalopatía de Wernicke-escorbuto, ¿una asociación infradiagnosticada?. <i>Neurología</i> , 2020, 35, 47-49.	0.3	0
8	Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3619-3621.e1.	2.0	7
9	Urticaria-like lesions in COVID-19 patients are not really urticaria – a case with clinicopathological correlation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e459-e460.	1.3	35
10	Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders. <i>Journal of Autoimmunity</i> , 2020, 111, 102472.	3.0	11
11	Comment on “Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital”. Pseudoherpetic Grover disease seems to occur in patients with COVID-19 infection. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 896-898.	0.6	16
12	Occupational pustular allergic contact dermatitis. <i>Contact Dermatitis</i> , 2020, 83, 54-55.	0.8	0
13	A case of naevus vascularis mixtus with hypotrophy and hypotrichosis due to mosaic GNA11 mutation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e420-e422.	1.3	8
14	Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement. <i>Cells</i> , 2020, 9, 1603.	1.8	10
15	Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients”. To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e253-e254.	0.6	35
16	Sequential appearance of small vessel vasculitis and neutrophilic panniculitis in a patient with rheumatoid arthritis: further insight into the mechanism of this infrequent panniculitis. <i>International Journal of Dermatology</i> , 2019, 58, e198-e200.	0.5	5
17	Tuberculosis re-screening in psoriatic patients under continuous biological therapy. Does the treatment modify the tuberculin skin test response?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e295-e296.	1.3	1
18	Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e215-e217.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1887-1892.	1.3	3
20	Induction of Light Tolerance Using Narrowband UV-B in Solar Urticaria. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 888-892.	0.2	0
21	Inducción de fototolerancia con ultravioleta B de banda estrecha en urticaria solar. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 888-892.	0.2	4
22	Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 584-601.	0.2	2
23	Mucinosi nodular asociada a gammapatía monoclonal de cadenas ligeras de significado incierto. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 272-273.	0.2	0
24	Eficacia y seguridad de omalizumab en un paciente con urticaria crónica espontánea e infección activa por el virus de la hepatitis B. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 383-384.	0.2	7
25	Omalizumab in the Treatment of Chronic Inducible Urticaria. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 423-431.	0.2	4
26	Prevalence of amyloid deposits determined by fine-needle aspiration of abdominal fat in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e280-e281.	1.3	0
27	No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab. <i>British Journal of Dermatology</i> , 2017, 177, 862-863.	1.4	6
28	Successful treatment to a tretinoin/clindamycin gel in a late onset of nevus comedonicus. <i>Dermatologic Therapy</i> , 2017, 30, e12486.	0.8	4
29	Efficacy and Safety of Omalizumab in a Patient With Chronic Spontaneous Urticaria and Active Hepatitis B Virus Infection. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 383-384.	0.2	3
30	Respuesta a omalizumab en 3 casos de urticaria solar. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, e53-e55.	0.2	9
31	Omalizumab en el tratamiento de la urticaria crónica inducible. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 423-431.	0.2	14
32	Long-term treatment of neurofibromatosis 1 with ketotifen. A report of three cases. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1092-1094.	0.7	2
33	Fast and sustained Improvement of Patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. <i>Dermatologic Therapy</i> , 0, , .	0.8	1